Huma Therapeutics today announced the development of Huma Intelligence Scribe, an AI-powered solution designed to transform the way clinical consultations are documented and understood. Huma Intelligence Scribe transcribes consultations in real time and generates actionable insights for both patients and healthcare providers leveraging NVIDIA AI infrastructure and models including NVIDIA Nemotron™ speech Parakeet and Titanet for automatic speech recognition (ASR) and speaker identification, and NVIDIA-optimized Llama models for embedding and reranking.

The solution produces two tailored summaries for each consultation. The Patient Summary simplifies medical terminology into language that is easy for patients to understand, supporting better comprehension and engagement. The Clinician Summary highlights key clinical points and suggests additional questions that can be asked to ensure a thorough evaluation, enhancing decision-making and efficiency.

Huma Intelligence Scribe is expected to begin pilot testing with select clinical partners in Q1 2026.

US Market Rollout: Early Adoption and Clinical Engagement

As part of the broader rollout of Huma Intelligence Scribe across the United States, the solution has already achieved meaningful adoption ,demonstrating strong early momentum in respiratory care. Adoption continues to grow among respiratory therapists and patients alike, supporting ongoing clinical engagement and structured follow-up care.

The program currently supports 38 active respiratory therapists and approximately 2,250 active patients across clinics in the United States and their partner networks. Patients engage with the platform on a consistent monthly basis, with approximately 2,300 live interaction notes generated each month, encompassing both onboarding sessions and ongoing follow-up consultations. This level of utilisation reflects a close alignment between clinician capacity and patient engagement, with interaction volumes tracking in step with the active patient base ,a meaningful early indicator of programme health and scalability.

Breaking Language Barriers in Clinical Care

A significant differentiator for Huma Intelligence Scribe is its broad multilingual capability. The solution currently supports consultations in 25 languages including Bulgarian (bg), Croatian (hr), Czech (cs), Danish (da), Dutch (nl), English (en), Estonian (et), Finnish (fi), French (fr), German (de), Greek (el), Hungarian (hu), Italian (it), Latvian (lv), Lithuanian (lt), Maltese (mt), Polish (pl), Portuguese (pt), Romanian (ro), Slovak (sk), Slovenian (sl), Spanish (es), Swedish (sv), Russian (ru), Ukrainian (uk),, ensuring that patients and clinicians can communicate naturally and accurately regardless of their primary language. This is particularly significant for the diverse US patient population, where language barriers remain a persistent challenge in delivering equitable, high-quality care. By removing this barrier at the point of clinical documentation, Huma Intelligence Scribe ensures that the quality and completeness of the clinical record is not compromised by language ,bringing accurate, AI-powered transcription to a far wider range of patients and care settings.

About Huma Therapeutics

Huma Therapeutics is a digital health company dedicated to improving patient outcomes and clinician efficiency through AI-driven solutions. Huma's award-winning, disease-agnostic cloud platform has earned major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. The platform supports over 4,500 hospitals and clinics and engages more than 50 million individuals across 70+ countries.

Media Contact

Dr. Farnaz Behroozi, Head of Pharma

farnaz.behroozi@huma.com